DCF Advisers LLC Takes $1.67 Million Position in Xencor, Inc. $XNCR

DCF Advisers LLC purchased a new position in shares of Xencor, Inc. (NASDAQ:XNCR) in the second quarter, Holdings Channel.com reports. The institutional investor purchased 103,736 shares of the biopharmaceutical company’s stock, valued at approximately $1,670,000.

Several other institutional investors have also recently added to or reduced their stakes in XNCR. BlackRock Inc. bought a new position in Xencor during the 2nd quarter valued at $219,785,000. Vanguard Group Inc. increased its position in shares of Xencor by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 7,165,450 shares of the biopharmaceutical company’s stock worth $109,703,000 after purchasing an additional 61,692 shares during the last quarter. BVF Inc. IL raised its stake in shares of Xencor by 160.3% in the 4th quarter. BVF Inc. IL now owns 7,133,720 shares of the biopharmaceutical company’s stock valued at $109,217,000 after purchasing an additional 4,393,579 shares in the last quarter. RTW Investments LP raised its stake in shares of Xencor by 8.9% in the 4th quarter. RTW Investments LP now owns 6,777,461 shares of the biopharmaceutical company’s stock valued at $103,763,000 after purchasing an additional 556,407 shares in the last quarter. Finally, State Street Corp lifted its position in shares of Xencor by 22.7% during the fourth quarter. State Street Corp now owns 4,507,254 shares of the biopharmaceutical company’s stock worth $69,006,000 after purchasing an additional 833,423 shares during the last quarter.

Xencor Stock Up 8.3%

Shares of XNCR stock opened at $27.52 on Thursday. The company has a market cap of $2.05 billion, a P/E ratio of -12.68 and a beta of 0.85. The business has a 50 day moving average of $17.61 and a two-hundred day moving average of $13.99. Xencor, Inc. has a 52 week low of $7.13 and a 52 week high of $27.59.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.51. The business had revenue of $51.22 million for the quarter, compared to analysts’ expectations of $18.89 million. Xencor had a negative return on equity of 28.66% and a negative net margin of 155.59%.The business’s quarterly revenue was up 17.4% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.41) EPS. Analysts expect that Xencor, Inc. will post -3 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently weighed in on XNCR. Truist Financial lowered their price objective on Xencor from $29.00 to $27.00 and set a “buy” rating for the company in a report on Tuesday, July 7th. Wedbush increased their target price on Xencor from $26.00 to $30.00 and gave the stock an “outperform” rating in a report on Thursday, August 6th. Wall Street Zen upgraded Xencor from a “strong sell” rating to a “hold” rating in a research report on Saturday, August 8th. Zacks Research upgraded Xencor from a “strong sell” rating to a “hold” rating in a report on Monday, July 6th. Finally, Royal Bank Of Canada upped their price target on Xencor from $19.00 to $20.00 and gave the company an “outperform” rating in a research report on Thursday, August 6th. Five research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $24.86.

Xencor Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.